Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma

Qian Zhou, Vivian W.Y. Lui, Winnie Yeo

Research output: Contribution to journalReview articlepeer-review

187 Scopus citations


Despite recent advances in the understanding of the biologic basis of hepatocellular carcinoma (HCC) development, the clinical management of the disease remains a major challenge. Deregulation of the PI3K/Akt/mTOR pathway, which is a prototypic survival pathway, is increasingly implicated in HCC carcinogenesis. In this article, we detailed the role of this pathway in the pathogenesis of HCC and provide an update on the preclinical and clinical development of various agents targeting this key survival/proliferation pathway, which include various PI3K inhibitors, Akt inhibitors and mTOR inhibitors for HCC. In addition, we highlighted the therapeutic potential of combination strategy for mTOR inhibitors with conventional chemotherapy, in particular, antimicrotubule agents, other molecular targeting agents, as well as radiotherapy.

Original languageEnglish (US)
Pages (from-to)1149-1167
Number of pages19
JournalFuture Oncology
Issue number10
StatePublished - Oct 2011
Externally publishedYes


  • combined targeting
  • hepatocellular carcinoma
  • PI3K/Akt/mTOR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this